Search
camostat mesylate (Q23731028)
Indications:
- candidate antiviral agent for treatment of COVID-19 [1]
Dosage:
- 100 mg PO BID used in children with hematuria & proteinuria
Mechanism of action:
- appears to inbibit transmembrane serine protease TMPRSS2
Notes:
- approved in Japan for chronic pancreatitis & postoperative reflux esophagitis
General
antiviral agent
Database Correlations
PUBCHEM cid=5284360
References
- Hoffmann M, Kleine-Weber H, Schroeder S
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked
by a Clinically Proven Protease Inhibitor.
Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4.
PMID: 32142651
- Wikidata: camostat mesylate
https://www.wikidata.org/wiki/Q23731028
- PubChem: 5284360
- Asami T, Tomisawa S, Uchiyama M.
Effect of oral camostat mesilate on hematuria and/or proteinuria in children.
Pediatr Nephrol 19, 313-316 2004
PMID: 14740285
https://link.springer.com/article/10.1007%2Fs00467-003-1377-9
- Yamawaki H, Futagami S, Kaneko K et al
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy
Improves Epigastric Pain in Early Chronic Pancreatitis and Functional
Dyspepsia with Pancreatic Enzyme Abnormalities.
Digestion. 2019;99(4):283-292. Epub 2018 Nov 2.
PMID: 30391941